Haemostatic, Endothelial and Lipoprotein Parameters and Blood Pressure Levels in Women with a History of Preeclampsia

Summary

To determine whether perturbations of haemostatic function and lipoprotein metabolism prevail long after preeclampsia and increase the risk of future coronary heart disease (CHD), we conducted a follow-up study in women with (cases, n = 25) or without (controls, n = 24) a history of preeclampsia. Blood samples were taken in the follicular and in the luteal phases of a menstrual cycle. Levels of blood pressure (BP) and proteinuria measured during the index pregnancy were included in the evaluation. Compared to control women who had undergone a normal pregnancy, the formerly preeclamptic patients had higher systolic (p <0.01) and diastolic (p <0.05) BPs and increased plasma levels of von Willebrand factor (vWF), fibrinogen, cholesterol, triglycerides and very low density lipoprotein (VLDL) (all p <0.05). The lipid, vWF, and fibrinogen levels were positively related to the degree of BP elevation but not to the degree of proteinuria during the index pregnancy. Except for the increase in vWF level, all biochemical perturbations were only present in the luteal but not in the follicular phase samples. In conclusion, persistent endothelial dysfunction with ensuing dysregulation of blood pressure, haemostatic perturbation and dyslipoproteinemia after preeclampsia may indicate a proneness to future CHD.

• References

• 1 Greer IA. Pathological Processes in Pregnancy-induced Hypertension and Intrauterine Growth retardation: “An Excess of Heated Blood”. In Haemostasis and Thrombosis in Obstetrics and Gynecology. Greer IA, Turpie AGG, Forbes CD. eds. London: Chapman & Hall Medical; 1992: 163-202.
• 2 Deng L, Bremme K, Hansson LO, Blombäck M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994; 84: 941-5.
• 3 He S, Bremme K, Blombäck M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coag Fibrinol 1997; 8: 232-8.
• 4 Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. Am J Obstet Gynecol 1996; 174: 975-82.
• 5 Sattar N, Bendomir A, Berry C, Shepherd J, Greer IA, Packard CJ. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol 1997; 89: 403-8.
• 6 Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165: 1408-12.
• 7 Svensson A, Andersch B, Hansson L. Prediction of later hypertension following a hypertensive pregnancy. J Hypert 1983; 1: 94-6.
• 8 Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74: 772-6.
• 9 Makris TK, Tsoukala C, Krespi P, Hatzizacharias A, Gialeraki A, Papargyriou J, Votteas V, Mandalaki T. Haemostasis balance disorders in patients with essential hypertension. Thromb Res 1997; 88: 99-107.
• 10 Ossei-Gerning N, Wilson IJ, Grant WP. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost 1998; 79: 736-40.
• 11 Moor E, Hamsten A, Blombäck M, Herzfeld I, Wiman B, Ryden L. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost 1994; 72: 335-42.
• 12 Moor E, Silveira A, van’t Hooft F, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
• 13 Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S. Lp(a) in hypertensive patients. J Human Hypert 1998; 12: 83-9.
• 14 Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81: 13-7.
• 15 Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7-12.
• 16 Blombäck M, Eneroth P, Landgren BM, Lagerström M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992; 67: 70-5.
• 17 Andersson O, Blombäck M, Bremme K, Wramsby H. Prediction of changes in levels of haemostatic variables during natural menstrual cycle and ovarian hyperstimulation. Thromb Haemost 1997; 77: 901-4.
• 18 Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892-8.
• 19 Clauss A. Gerinungsphysiologische Schnellmethode. Zur Bestimmung des Fibrinogens. Acta Haemat 1957; 5: 237-46.
• 20 Silveira A, Yamamoto T, Adamson L, Hessel B, Blombäck B. Application of an enzyme-linked immunosorbent assay (ELISA) to von Willebrand factor (vFW) and its derivatives. Thromb Res 1986; 43: 91-102.
• 21 Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72: 734-9.
• 22 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
• 23 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-5.
• 24 Korninger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-35.
• 25 Doolittle RF. Fibrinogen and Fibrin. In Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Edinburgh: Churchill Livingstone; 1994: 491-513.
• 26 Ludlam CA. Assessement of Platelet Fuction. In Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Edinburgh: Churchill Livingstone; 1994: 199-215.
• 27 Lowe GD, Rumley A, Tooke J. Clinical pathophysiology of arterial disease. In A Textbook of Vascular Medicine. Tooke J, Lowe GD. eds. London: Arnold; 1996: 43-59.
• 28 Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-6.
• 29 National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 1990; 163: 1689-712.
• 30 Redman CWG. Hypertension in pregnancy. In Medical Disorders in Obstetric Practice. de Swiet M. ed. London: Blackwell Scince; 1995: 182-225.
• 31 Redman CWG, Roberts JM. Management of preeclampsia. Lancet 1993; 341: 1451-4.
• 32 Lindheimer MD. Hypertension in pregnancy. Hypertension 1993; 22: 127-37.
• 33 Sullivan CA, Magann EF, Perry JR KG, Roberts WE, Blake PG, Martin JR JN. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstetr Gynecol 1994; 171: 940-3.
• 34 Mehta L, Young ID. Recurrence risks for common complications of pregnancy – a review. Obstet Gynecol Survey 1987; 42: 218-23.